GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Total Current Assets

Benevolent AI (Benevolent AI) Total Current Assets : $115.68 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Benevolent AI's total current assets for the quarter that ended in Dec. 2023 was $115.68 Mil.


Benevolent AI Total Current Assets Historical Data

The historical data trend for Benevolent AI's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Total Current Assets Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial 132.66 133.53 75.30 185.24 115.68

Benevolent AI Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only 75.30 236.23 185.24 145.82 115.68

Benevolent AI Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Benevolent AI's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Benevolent AI's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Benevolent AI  (GREY:BAIVF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Benevolent AI's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=46.173-37.418+0.75 * 0+0.5 * 0
=8.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benevolent AI Total Current Assets Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Benevolent AI (Benevolent AI) Business Description

Comparable Companies
Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.